A recent study from the Department of Pathology, Columbia University, New York, New York, USA; Department of Dermatology, Columbia University, New York, New York, USA; and Department of Medicine, Columbia University, New York, New York, USA shows that “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.”
This study was published in the August, 17 2014 issue of Nature Medicine (The number 1 journal in Medicine with an IF of ~35) by Prof. Clynes R, Xing L and others from the Department of Pathology, Columbia University, New York, New York, USA; Department of Dermatology, Columbia University, New York, New York, USA; and Department of Medicine, Columbia University, New York, New York, USA
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNAs-based therapy for Alopecia areata: A pharmacological mixture containing miRNA-375 and miRNA-107 reverses Alopecia areata via down regulation of its target genes. This study suggests, for the first time, that miRNA-375 and miRNA-107, by up regulating their target genes, they may reverse alopecia areata. Together, this study suggests that pharmacological formulations encompassing “ miRNA-375 and miRNA-107 or small molecule compounds that activate the expression of miRNA-375 and miRNA-107“ may be used to treat Alopecia areata.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., MiRNAs-based therapy for Alopecia areata: A pharmacological mixture containing miRNA-375 and miRNA-107 reverses Alopecia areata via down regulation of its target genes, Genome-2-Bio-Medicine Discovery center (GBMD), 26/08/2014, 14.26, http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
